General
Preferred name
COPANLISIB
Synonyms
BAY 84-1236, BAY-80-6946, BAY 80-6946, Copanlisib hydrochloride ()
BAY 80-6946 dihydrochloride ()
BAY 80-6946 ()
COPANLISIB HYDROCHLORIDE ()
Copanlisib (dihydrochloride) ()
BAY 80-6946 (dihydrochloride) ()
Copanlisib dihydrochloride ()
COPANLISIB TRIS-HCLBAY-80-6946 TRIS-HCLALIQOPA ()
BAY-80-6946 ()
BAY80-6946 ()
Aliqopa ()
Copanlisib hydrochloride hydrate ()
BAY 84-1236 ()
BAY-84-1236 ()
BAY-80-6946 DIHYDROCHLORIDE ()
P&D ID
PD012595
CAS
1032568-63-0
1402152-13-9
Tags
available
drug
Approved by
FDA
First approval
2017
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Mantle cell lymphoma
neoplasm of mature B-cells
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 70
PRICE 75
DESCRIPTION Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is an ATP-competitive pan-class I PI3K inhibitor, with IC50 values of 0.5 nM for PI3K??, 0.7 nM for PI3K??, 3.7 nM for PI3K??, and 6.4 nM for PI3K??. It exhibits superior antitumor activity and demonstrates more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR.
DESCRIPTION Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. (PKIDB)
DESCRIPTION Copanlisib (BAY 80-6946) is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. By inhibiting the PI3K signaling pathway, Copanlisib may impede tumor cell growth and survival in certain tumor populations. Dysregulated PI3K signaling, often linked to tumorigenesis, may also contribute to tumor resistance to various antineoplastic agents. (TargetMol Bioactive Compound Library)
DESCRIPTION Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved to treat follicular lymphoma that has relapsed after treatment with at least two other anticancer therapies. (BOC Sciences Bioactive Compounds)
DESCRIPTION Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is an ATP-competitive pan-class I PI3K inhibitor, with IC50 values of 0.5 nM for PI3Kα, 0.7 nM for PI3Kδ, 3.7 nM for PI3Kβ, and 6.4 nM for PI3Kγ. It exhibits superior antitumor activity and demonstrates more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. (TargetMol Bioactive Compound Library)
Cell lines
5
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
A11766
BOC Sciences Bioactive Compounds
copanlisib-hydrochloride-cas-1402152-13-9-item-7199
Cayman Chemical Bioactives
20354
ChEMBL Approved Drugs
CHEMBL3218576
CHEMBL3545068
ChEMBL Drugs
CHEMBL3218576
CHEMBL3545068
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DB12483
DrugBank Approved Drugs
DB12483
DrugCentral
5256
DrugCentral Approved Drugs
5256
EUbOPEN Chemogenomics Library
EUB0001179
MedChem Express Bioactive Compound Library
HY-15346
HY-15346A
NCATS Inxight Approved Drugs
WI6V529FZ9
NIH Approved Oncology Drugs
440816497
PKIDB
ReFrame library
TargetMol Bioactive Compound Library
T6322
T14998
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
480.22
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
2
cLogP
0.66
TPSA
139.79
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PIK3CA,PIK3CB,PIK3CD,PIK3CG
Target
Apoptosis
PI3K
PI3Kα
PI3Kβ
PI3Kγ
PI3Kδ
PI3K¦Á
PI3K¦Â
PI3K¦Ã
PI3K¦Ä
PIK3CA, PIK3CB, PIK3CD, PIK3CG
PIK3CA
PIK3CB
MTOR
Indication
follicular lymphoma
MOA
PI3K inhibitor
Pathway
PI3K/Akt/mTOR signaling
PI3K/Akt/mTOR
Recommended Cell Concentration
100 nM
Source data